Newsgroup: it.scienza.medicina
Titolo: Cura Leucemia Mieloide Cronica con STI

Vorrei notizie circa l'applicazione di questa nuovissima terapia ed i
risultati ottenuti da coloro che l'hanno praticata.
Desidero informazioni urgenti in quanto un mio congiunto deve decidere se
sottoporsi a tale terapia per curare tale malattia.
Rispondete in email.
Grazie

Rispondete in email.
Per cortesia, risposte sul newsgroup, come indicato dalla netiquette.
Si tratta di un gruppo di discussione di pubblico accesso e quindi la
discussione deve rimanere pubblica. Qualcuno potrebbe avere lo stesso
problema e cercare le stesse risposte
-- 
paolo,
Moderatore di it.scienza.medicina
mailto: 
pde...@iol.it
UIN: 50157603 --- Linux user 180069

...
Salve a tutti, ciao Gitano
Ho una della CNN riguardo al STI 571 della Novartis. Non so come te la
cavi con l'inglese.
In bocca al lupo!
Alessio
Drug shows promise against one form of leukemia
December 3, 1999
Web posted at: 12:13 p.m. EST (1713 GMT)
------------------------------------------------------------------------
--------
'Too good to be true'
'Literally given me my life back'
------------------------------------------------------------------------
--------
NEW ORLEANS (CNN) -- Cancer researchers on Friday reported dramatic
results in early clinical trials of an experimental pill designed to
combat chronic myelogenous leukemia, one of four common forms of
leukemia. The drug has few side effects and may have the potential to
destroy other cancers, medical experts said.
 MORE INFORMATION:
Patients and physicians can get more information on the Leukemia drug
study by calling the Novartis Oncology Clinical Trials Hotline at
1-800-340-6843
 or going to 
www.novartisoncology.com
.
Those outside the U.S. can contact the Medical Department of the local
Novartis Pharma Company or consult the "contact us" section of the
company's website: 
www.pharma.novartis.com
.
The findings are being presented in New Orleans, at the annual meeting
of the American Society of Hematology.
In a study of 37 patients treated with the drug, code-named STI-571, all
of them had complete normalization of their blood counts, signaling a
remission of their leukemia.
"In every single one of them, their blood counts have returned to normal
within one month of starting therapy and (in) a significant number of
them, we've actually seen the molecular cause of this leukemia begin to
disappear," said one of the researchers, Dr. Brian Druker of Oregon
Health Sciences University.
Unlike traditional, toxic chemotherapy treatments, which kill both
cancerous and healthy cells, STI-571 specifically targets an enzyme
found only in leukemia cells, meaning patients suffer minimal side
effects.
In one phase of the experiment, chronic myelogenous leukemia (CML)
patients with early stages of the disease who failed to respond to
traditional interferon treatment received STI-571 in pill form once a
day.
Patients experienced little or no toxicity, and most of those receiving
doses at 200 mg or higher had white cell blood counts come down to
normal, researchers said.
They said the molecular cause of CML begin to disappear at doses of 300
mg or more. "One of the problems I've had with this project is that I
often times have difficulty convincing people that this isn't too good
to be true," Druker told CNN.
'Literally given me my life back'
Garner says the experimental drug has had no side effects for her
Leukemia patient Virginia Garner, who was dying from leukemia just
months ago and did not respond to interferon, is enthusiastic about the
experimental drug. "(It) has no side effects whatsoever. It's literally
given me my life back," she told CNN.
Chronic myelogenous leukemia, which prevents blood cells from maturing
normally, is more common in middle-aged and elderly people. The only
major symptom is extreme fatigue.
The end stage of the disease, known as the blast crisis, can be fatal
within several months.
More tests needed
Some experts think the preliminary success of STI-571 shows the
treatment for chronic myelogenous leukemia could work for other cancers
as well.
"We're hopeful that opening this new door will result in a cure of
chronic myelogenous leukemia and thus pave the way for additional drug
developments in cancer," said Dr. Harmon Eyre, chief medical officer of
the American Cancer Society.
Before that can happen, though, researchers say they need more time to
see if the preliminary results hold up under long-term studies with more
patients.
The next phase of testing, involving 19 medical centers in the United
States and Europe, is set to begin this month.
The study was funded by the National Institutes of Health, the Leukemia
Society, and Novartis, a pharmaceutical company.
Medical Correspondent Rhonda Rowland contributed to this report.

sottoporsi a tale terapia per curare tale malattia.
Dimenticavo...
Se non sbaglio, in Italia dovrebbero essere in corso esperimenti sul STI
571 all'ospedale S.Raffaele -Milano-.
Buona domenica, Alessio